However, the development of resistance to ROS1 inhibitors remains an urgent focus of clinical research, since the only remaining clinical interventions for ROS1 inhibitor-resistant cancers are chemotherapy or locally ablative therapy 12. The gene discussed is ROS1; the disease is cancer.